Stocks rose on Monday morning on more positive vaccine news after AstraZeneca reported that its coronavirus vaccine candidate, developed with the University of Oxford, was 70.4% effective in preventing infection in late-stage trials. The vaccine may have even higher efficacy under a different dosing regimen and also has less stringent storage requirements than those developed by Pfizer/BioNTech and Moderna. On the economic front, IHS Markit reported stronger-than-expected readings in both its manufacturing a